维普期刊资源整合服务平台（V6.5）

77篇 您的检索式：作者名="Sequist L"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Genotypic and histological evolution lung cancers acquiring resistance to EGFR inhibitors显示文摘	SEQUIST L V WALTMAN B A DIAS-SANTAGATA D	2011	Sci Transl Med2011，3，75：	1
2	EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story显示文摘	Sequist L V Lynch T J	2008	Annu Rev Med2008，59，：	1
3	First-in-hunmn evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M ) 显示文摘	Sequist L Soria JC Gadgeel SM	2014	J Clin Oncol2014，32，5：	1
4	Neratinib,an irreversible pan-Erb B receptor tyrosine kinase inhibitor;Result of a phaseⅡtrial in patients with advanced non-small-cell lung cancer显示文摘	Sequist L V Besse B Lynch T J	2010	J Clin Oncol2010，28，18：	1
5	Isolation of rare circulating tumour cells in cancer patients by microchip technology显示文摘	NAGRATH S SEQUIST L V MAHESWARAN S	2007	Nature2007，450，7173：	1
6	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations显示文摘	Sequist L V Martins R G Spigel D	2008	J Clin Oncol2008，26，15：	1
7	Mucinous differentia-tion correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features显示文摘	Finberg K E Sequist L V Joshi V A	2007	J Mol Diagn2007，9，3：	1
8	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non- small-cell lung cancer显示文摘	Sequist L V Besse B Lynch T J	2010	J Clin Onco12010，28，18：	1
9	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib 显示文摘	Jackman D M Yeap B Y Sequist L V	2006	Clin Cancer Res2006，12，13：	1
10	Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib 显示文摘	Jackman DM Cioffredi L Sequist LV	2008	J Clin Oncol2008，26，15：	1
11	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations 显示文摘	SEQUIST L V MARTINS R G SPIGEL D	2008	J Clin Oncol2008，26，15：	1
12	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib显示文摘	Jackman D M Yeap B Y Sequist L V	2006	Clin Cancer Res2006，12，13：	1
13	Mucinous dif- ferentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features 显示文摘	Finberg K E Sequist L V Joshi V A	2007	J Mol Diagn2007，9，3：	1
14	Isolation of rare circu- lating tumour cells in cancer patients by microchip technology显示文摘	Nagrath S Sequist L V Maheswaran S	2007	Nature2007，450，7173：	1
15	First-line ge- fitinib in patients with advanced non- small- cell lung cancer harboring somatic EGFR mutations显示文摘	SEQUIST L V MARTINS R G SPIGEL D	2008	J Clin Oncol2008，26，15：	1
16	Detection of mutations in EGFR in circulating lung-cancer cells 显示文摘	Maheswaran S Sequist L V Nagrath S	2008	New England Journal of Medicine2008，359，4：	1
17	Detection of mutations in EGFR in circulating lung-cancer cells 显示文摘	Maheswaran S Sequist L V Nagrath S	2008	NEJM2008，359，4：	1
18	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor : results of a phase IItrial in patients with advanced non-small-cell lung cancer显示文摘	Sequist L V Besse B Lynch T J	2010	J Clin On-col2010，28，18：	1
19	First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations显示文摘	SEQUIST L V MARTINS R G SPIGEL D	2008	J Clin Oncol2008，26，15：	1
20	Acquired resistance to TKIs in solid tumours, learning from lung cancer显示文摘	CAMIDGE D R PAO W SEQUIST L V	2014	Nat Rev Clin Oncol2014，11，8：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示